Benzinga | Mar 1, 2021 10:45AM EST

Evercore ISI Group Upgrades Biomarin Pharmaceutical to Outperform, Raises Price Target to $100

Evercore ISI Group analyst Joshua Schimmer upgrades Biomarin Pharmaceutical (NASDAQ:BMRN) from In-Line to Outperform and raises the price target from $90 to $100.